高危人乳头瘤病毒在宫颈癌筛查中的应用及卫生经济学评价  

Application of cytology combined with high risk-human pappiloma virus testing in cervical cancer and its health economic evaluation

作　　者：姜敏[1] 于民[1] 

机构地区：[1]克拉玛依市中心医院病理科,新疆克拉玛依834000

出　　处：《国际病理科学与临床杂志》2010年第4期351-354,共4页Journal of International Pathology and Clinical Medicine

摘　　要：据2002年数据统计,全球估计有49万的子宫颈癌新发病例,超过27万妇女死于该病。目前高危人乳头瘤病毒(high risk-human pappiloma virus,HR-HPV)联合细胞学检测是大多数发达国家和发展中国家经济发达地区妇女首选的子宫颈癌筛查方案。研究显示,HPV检测可明显提高宫颈高度病变的检出率,提高细胞学检查的敏感性,从卫生经济学角度来看,两者联合检测是一个低本高效的方案,HR-HPV与细胞联合检测是目前宫颈癌筛查的最佳选择,但仍存在一定的局限性。About 490 000 cases of cervical cancer are newly diagnosed world wide according to statistical data in 2002 and more than 270 000 cases died of this disease.Till now,（high risk-human pappiloma virus,HR-HPV） is the preferred screening approach for cervical cancer in most developed countries and some rich regions of developing countries.It has been shown that the HPV DNA test could increase the detection rate of high-grade cervical intraepithelial neoplasia and raise the sensitivity of cytology.Based on the view of the health economics,the combination of cytology with HPV test is the best option and the most effective with low cost approach for the detection of cervical lesion so far,although it is not perfect.

关 键 词：高危人乳头瘤病毒 宫颈上皮内瘤变 宫颈癌前病变 宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]